Moreover, significant clinical response to PD-1 inhibition and subsequent increased survival was found in patients with PD-L1− non-small cell lung cancer and this response, in some cases, was superior to that in PD-L1+ patients [78]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.